1. CalciMedica to present at AKI & CRRT Conference on March 3. 2. Presentation focuses on the role of ORAI-1 in acute kidney injury. 3. Auxora™ shows consistent positive results in multiple clinical trials. 4. Currently conducting various Phase 2 trials for inflammatory diseases.
The presentation highlights CalciMedica's expertise, potentially increasing investor confidence, similar to past positive conferences.
The conference presentation showcases significant research, crucial for building market trust in CALC's therapies.
Investor response to the conference could lead to immediate stock movements, akin to previous major announcements.
CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a plenary presentation at the 30th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) being held March 3-6, 2025 in San Diego, CA.
Presentation Title: The Role of ORAI-1 in AKI
Presenter: Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica
Session Title: Plenary 2: Bench to Bedside: Translating Discoveries to Clinical Care
Session Date and Time: Monday, March 3, 10:35-10:55 a.m. PT
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS). The Company has also completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT). CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.
Argot Partners
Sarah Sutton/Kevin Murphy
(212) 600-1902
SOURCE CalciMedica, Inc.